Agenus (AGEN) to Release Quarterly Earnings on Tuesday

Agenus (NASDAQ:AGEN) is projected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of $2.63 per share and revenue of $80.3870 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:30 AM ET.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The firm had revenue of $25.70 million for the quarter, compared to analyst estimates of $49.71 million. On average, analysts expect Agenus to post $-13 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Agenus Stock Performance

Shares of Agenus stock traded down $0.20 during midday trading on Tuesday, reaching $3.77. 112,990 shares of the company’s stock traded hands, compared to its average volume of 729,878. The company has a market cap of $120.25 million, a price-to-earnings ratio of -0.53 and a beta of 1.43. The company’s 50 day simple moving average is $4.22 and its 200 day simple moving average is $4.44. Agenus has a 52 week low of $1.38 and a 52 week high of $7.34.

Institutional Trading of Agenus

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. Invesco Ltd. acquired a new stake in Agenus in the 1st quarter worth $88,000. AQR Capital Management LLC grew its position in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 427,604 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Agenus in the 1st quarter worth $58,000. JPMorgan Chase & Co. grew its position in Agenus by 608.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 78,637 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 67,530 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Agenus during the 2nd quarter valued at about $1,976,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AGEN. Zacks Research upgraded shares of Agenus to a “hold” rating in a research note on Tuesday, August 12th. HC Wainwright reiterated a “buy” rating on shares of Agenus in a research note on Monday, October 20th. Wall Street Zen lowered shares of Agenus from a “buy” rating to a “hold” rating in a research note on Sunday, August 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Agenus in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $14.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.